The background rate of pancreatitis in the general population, especially among people with obesity and type 2 diabetes who use these medications, is already elevated by the underlying conditions themselves
Results: Oral semaglutide reduced HbA1c levels compared to placebo Oral semaglutide patients experienced significant weight loss compared to those on placebo The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% of patients in the oral semaglutide group and 4.8% in the placebo group, which showed that cardiovascular safety of oral semaglutide was non-inferior to placebo
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications primarily used for managing type 2 diabetes and, in some formulations, for chronic weight management
Once you break that chain, different rules apply
Missing your weekly injection by just two or three days usually causes minimal disruption, but gaps longer than a week can undo weeks of metabolic adaptation